The study provides a comprehensive analysis of diabetes trends among adolescents aged 10–24 years. Using data from the Global Burden of Disease (GBD) 2021 study, it estimates the prevalence, disability-adjusted life years (DALYs), and risk factors for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) across 204 countries and territories. The findings reveal a significant increase in the global burden of adolescent diabetes, with 3.4 million living with T1DM and 14.6 million with T2DM in 2021. By 2030, these numbers are projected to rise to 3.7 million and 20.9 million, respectively.
A recent study examined the effects of combining the diabetes medication dapagliflozin with a calorie-restricted diet on achieving remission of type 2 diabetes. Conducted at 16 centers in China, the randomized, double-blind, placebo-controlled trial involved 328 patients with type 2 diabetes, aged 20-70, who were either overweight or obese. Participants received either dapagliflozin (10 mg/day) or a placebo with a 500-750 kcal/day diet.
This study looked at how people who have had heart attacks understand their risk of getting diabetes. The researchers studied 466 heart attack patients in Augsburg, Germany, and found some concerning results.
Researchers conducted a study to understand if the diabetes medication empagliflozin affects eye problems (specifically diabetic retinopathy) in people with type 2 diabetes. Diabetic retinopathy is a condition where high blood sugar damages the blood vessels in the back of the eye, potentially leading to vision loss.
The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment
The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment
